Eli Lilly (LLY) Stock Could Be 28% Undervalued As Guidance Rises
Eli Lilly stock has climbed very sharply over the past five years, yet the current valuation checks send a more measured signal, with the Discounted Cash Flow (DCF) estimate pointing to meaningful upside while market based multiples sit closer to fair value. That mix leaves investors weighing a strong price run against an intrinsic value estimate that suggests the shares may still trade below what the underlying cash flows imply.
- Eli Lilly has returned about 3.7x over the past 5 years, which sets a high bar for any further gains to be justified by fundamentals.
- Ongoing demand for GLP 1 obesity and diabetes treatments can support expectations for future cash flows, while execution and pricing risks around this concentrated growth engine may limit how much investors are willing to pay.
- The company scores 4 out of 6 on the valuation checks, which points to a mixed picture rather than a clear bargain or a clearly expensive stock.
The issue now is whether Eli Lilly's recent share price leaves enough upside relative to the current intrinsic value estimate to make the valuation attractive.
Is Eli Lilly Still Cheap on Cash Flow?
The Discounted Cash Flow (DCF) model looks at Eli Lilly through the cash it is expected to generate for shareholders over time. On this view, the company’s latest twelve-month free cash flow sits at about $13.6b, and analysts expect that figure to keep growing rather than flattening out. Feeding those projections into a 2 Stage Free Cash Flow to Equity framework produces an estimated intrinsic value of about $1,654 per share.
That figure sits meaningfully above the recent share price, which implies the stock trades at roughly a 28.3% discount to this cash flow based estimate. Eli Lilly’s recent Q2 2026 update, with strong demand for GLP 1 treatments and raised guidance, is one factor that helps explain why the DCF supports a higher value than where the market currently prices the stock.
On this cash flow based view, Eli Lilly stock appears undervalued relative to the intrinsic value implied by the DCF model.
Our Discounted Cash Flow (DCF) analysis suggests Eli Lilly is undervalued by 28.3%. Track this in your watchlist or portfolio, or discover 52 more high quality undervalued stocks.
Is Eli Lilly Fairly Priced on Earnings?
P/E is a useful cross check for Eli Lilly because earnings are a key driver of how investors value large, profitable pharmaceutical companies. Right now Eli Lilly trades on a P/E of about 39.6x, which is far above the wider Pharmaceuticals industry average of 17.1x but sits slightly below the peer group average of 44.8x.
The model based fair P/E for Eli Lilly is about 39.7x, which is very close to the current multiple. That fair ratio already reflects the company’s scale, profitability and risk profile, so the small gap suggests the market is largely in line with what this framework would expect investors to pay for its earnings.
On this P/E lens, Eli Lilly appears roughly fairly valued, with the current price implying about the earnings multiple that the model suggests is reasonable.
See what the numbers say about this price — find out in our valuation breakdown.
The Eli Lilly Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where Eli Lilly's valuation puzzle leaves off. They set out in plain terms what future growth, margins and earnings would need to look like for the stock to be worth meaningfully more or less than today's price, and sit on Eli Lilly's Community page. Each one anchors a fair value to a specific story about Eli Lilly's potential catalysts and risks, so you can track which version of events is actually unfolding over time.
The Eli Lilly community is split between a GLP 1 driven upside story and a more cautious view that focuses on pricing and concentration risks.
Bull case: roughly fairly valued
"Market penetration for all GLP-1 drugs is only at 4% of target audience of 100 to 120 million people in the USA alone…"
Read the full Bull Case to see why Eli Lilly could be undervalued
Bear case: 32% overvalued
"The likelihood of significant drug pricing reforms in the U.S., combined with initiatives to increase pricing parity between the U.S. and Europe, threatens to sharply limit Eli Lilly's future pricing power…"
Read the full Bear Case to see why Eli Lilly could be overvalued
Do you think there's more to the story for Eli Lilly? Head over to our Community to see what others are saying!
The Bottom Line
Eli Lilly’s Discounted Cash Flow (DCF) estimate points to meaningful intrinsic value upside, while the P/E check says the stock now trades at about the earnings multiple that already reflects its quality and risks. That mix is what makes the valuation feel more mixed than outright cheap after such a strong share price move. The key question from here is whether Eli Lilly can sustain GLP 1 driven cash flows without pricing or concentration risks eroding the case that the current discount to intrinsic value is a genuine opportunity, rather than the market simply pricing in those uncertainties.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com